Evidence map›Paper›PMID 26366057›Full record

ArticleDrug design, development and therapy2015

Paeonia lactiflora Pall. protects against ANIT-induced cholestasis by activating Nrf2 via PI3K/Akt signaling pathway.

Xiao Ma, Yan-ling Zhao, Yun Zhu, Zhe Chen, Jia-bo Wang, Rui-yu Li, Chang Chen, Shi-zhang Wei, Jian-yu Li, Bing Liu and 4 more

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Exploring the Potential Mechanisms of Action ofCombinatorial chemistry & high throughput screening · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. The Study of a Novel Paeoniflorin-Converting Enzyme fromMolecules (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Mechanism ofFrontiers in nutrition · 2021
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Xiao MaPharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China ; Department of Pharmacy, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Yan-ling ZhaoDepartment of Pharmacy, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Yun ZhuDepartment of Integrative Medical Center, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Zhe ChenPharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China ; Department of Pharmacy, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Jia-bo WangChina Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Rui-yu LiPharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China ; China Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Chang ChenPharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China ; Department of Pharmacy, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Shi-zhang WeiPharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China ; Department of Pharmacy, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Jian-yu LiDepartment of Integrative Medical Center, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Bing LiuSchool of Chinese Medicine, The University of Hong Kong, Hong Kong.
Rui-lin WangDepartment of Integrative Medical Center, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Yong-gang LiDepartment of Integrative Medical Center, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Li-fu WangDepartment of Integrative Medical Center, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
Xiao-he XiaoChina Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation Army, Beijing, People's Republic of China.
University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPaeonia lactiflora Pall. (PLP), a traditional Chinese herbal medicine, has been used for hepatic disease treatment over thousands of years. In our previous study, PLP was shown to demonstrate therapeutic effect on hepatitis with severe cholestasis. The aim of this study was to evaluate the antioxidative effect of PLP on alpha-naphthylisothiocyanate (ANIT)-induced cholestasis by activating NF-E2-related factor 2 (Nrf2) via phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. MATERIALS AND

methodsLiquid chromatography-mass spectrometry (LC-MS) was performed to identify the main compounds present in PLP. The mechanism of action of PLP and its therapeutic effect on cholestasis, induced by ANIT, were further investigated. Serum indices such as total bilirubin (TBIL), direct bilirubin (DBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (γ-GT), and total bile acid (TBA) were measured, and histopathology of liver was also performed to determine the efficacy of treatment with PLP. Moreover, in order to illustrate the underlying signaling pathway, liver glutathione (GSH) content and mRNA or protein levels of glutamate-cysteine ligase catalytic subunit (GCLc), glutamate-cysteine ligase modulatory subunit (GCLm), Akt, heme oxygenase-1 (HO-1), NAD(P)H/quinone oxidoreductase 1 (Nqo1), and Nrf2 were further analyzed. In addition, validation of PLP putative target network was also performed in silico.

resultsFour major compounds including paeoniflorin, albiflorin, oxypaeoniflorin, and benzoylpaeoniflorin were identified by LC-MS analysis in water extract of PLP. Moreover, PLP could remarkably downregulate serum levels of TBIL, DBIL, AST, ALT, ALP, γ-GT, and TBA, and alleviate the histological damage of liver tissue caused by ANIT. It enhanced antioxidative system by activating PI3K/Akt/Nrf2 pathway through increasing Akt, Nrf2, HO-1, Nqo1, GCLc, and GCLm expression. The putative targets network validation also confirmed the important role of PLP in activating Akt expression.

conclusionThe potential mechanism of PLP in alleviating ANIT-induced cholestasis could to be related to the induction of GSH synthesis by activating Nrf2 through PI3K/Akt-dependent pathway. This indicates that PLP might be a potential therapeutic agent for cholestasis.

Indexed as

1-NaphthylisothiocyanatePaeoniaAnimalsAntioxidantsBiomarkersCholestasisDisease Models, AnimalDose-Response Relationship, DrugGlutathioneLiverMaleNF-E2-Related Factor 2Oxidative StressPhosphatidylinositol 3-KinasePhytotherapyPlant Extracts1-NaphthylisothiocyanateAntioxidantsBiomarkersGlutathioneNfe2l2 protein, ratNF-E2-Related Factor 2Phosphatidylinositol 3-KinasePlant ExtractsProto-Oncogene Proteins c-aktAktantioxidationcholestatic hepatitisNrf2Paeonia lactiflora Pall

Identifiers

PMID26366057
PMCPMC4562737
OpenAlexW1696748345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.